Repligen Corporation Roars Back in China—Will This Unlock Its Next Growth Wave?

Repligen Corporation reported robust financial performance for the third quarter of 2025, demonstrating strong organic growth across its business segments. The company’s revenue reached $189 million, marking a 22% year-over-year increase, with organic growth excluding acquisitions and currency impacts standing at a healthy 18%. This impressive growth can be attributed to broad-based strength across all franchises and geographies, with every segment experiencing double-digit growth. Notably, the analytics franchise led with over 50% growth, driven by innovations such as the SoloVPE PLUS in protein concentration analytics. Repligen’s strategic emphasis on leveraging its diverse portfolio, which supports the full spectrum of bioprocessing workflows, appears to be paying off. The company highlighted significant growth in its consumables and capital equipment segments, with capital equipment growing over 20%.